Loading…
Loading…
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for KIO and 80,000+ other tickers.
See exactly how KIO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for KIO and 80,000+ other tickers.
KKR Income Opportunities Fund is a close ended fixed income mutual fund launched by Kohlberg Kravis Roberts & Co. L.P. The fund is managed by KKR Asset Management LLC. It invests in fixed income markets and hedging markets across the globe. The fund primarily invests in first- and second-lien secured loans, unsecured loans and high yield corporate debt instruments. It employs fundamental analysis, with a focus on dynamic hedging strategies to create its portfolio. KKR Income Opportunities Fund was formed on March 17, 2011 and is domiciled in the United States.
NEW YORK--(BUSINESS WIRE)--KKR Income Opportunities Fund (the “Fund”) (NYSE: KIO) today announced its monthly distributions of $0.1215 per common share, payable on the dates below. Based on the Fund's current share price of $10.97 per share (as of market close on September 9, 2026), the distributions represent an annualized distribution rate of 13.29% (calculated by annualizing the distribution amount and dividing it by the current price). The monthly distribution schedule is as follows for the.
Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation (CKD). CKD, based in Seoul, is one of South Korea's leading pharmaceutical companies.
KKR Income Opportunities Fund (NYSE: KIO - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $11.24 and traded as low as $11.20. KKR Income Opportunities Fund shares last traded at $11.2130, with a volume of 366,158 shares traded. KKR Income
The KKR Income Opportunities Fund offers a 12.95% yield but has suffered NAV and price declines, raising concerns about distribution sustainability. KIO's portfolio blends floating-rate senior loans and fixed-rate junk bonds, positioning it to benefit modestly from potential Fed rate hikes. Recent performance has lagged peers, with the fund paying out more than it earns, leading to destructive distributions and NAV erosion.
Data Presented at Epilepsy Foundation Pipeline Conference Demonstrated Significant Reduction in Epileptiform Activity: KIO-300 is the active pharmaceutical ingredient of KIO-301, Kiora's ongoing Phase 2 clinical program in vision restoration in patients with gene mutation-agnostic Retinitis Pigmentosa Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator platform, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.